Factors influencing survival of 107 HER2 positive breast cancer patients treated with trastuzumab based neoadjuvant chemotherapy

被引：1
|
作者：
Favier, L. [1 ]
Guiu, S. [1 ]
Dunach, E. [1 ]
Assous, D. [1 ]
Bonnetain, F. [1 ]
Gligorov, J. [2 ]
Stockmeier, V. [3 ]
Vasseur, B. [4 ]
Fumoleau, P. [1 ]
Coudert, B. [1 ]
机构：
[1] Ctr Georges Francois Leclerc, Dijon, France
[2] Hop Tenon, F-75970 Paris, France
[3] Lab Sanofi Aventis, Paris, France
[4] Lab Roche, Paris, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70820-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5058
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [31] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [32] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer
    Fujita, Tetsuji
    LANCET, 2012, 379 (9833): : 2237 - 2237
  • [33] PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer
    Earl, H. M.
    Cameron, D. A.
    Miles, D.
    Wardley, A. M.
    Ogburn, E. R. M.
    Vallier, A-L
    Loi, S.
    Higgins, H. B.
    Hiller, L.
    Dunn, J. A.
    CANCER RESEARCH, 2012, 72
  • [34] Retrospective analysis of complete pathological response in locally advanced HER2 positive breast cancer patients treated with neoadjuvant chemotherapy associated to trastuzumab at Brazilian National Cancer Institute
    Nunes, A. S.
    Goncalves, A.
    Ominelli, J.
    Costa, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] PROGNOSTIC IMPACT OF HER2 IMMUNOREACTIVITY IN HER2-POSITIVE GASTRIC CANCER TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY
    Kadowaki, Shigenori
    Narita, Yukiya
    Komori, Azusa
    Nomura, Motoo
    Taniguchi, Hiroya
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Niwa, Yasumasa
    Muro, Kei
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] Changes of the white blood cells subsets in HER2 positive breast cancer patients treated with trastuzumab
    Matic, I.
    Grujic, M.
    Kolundzija, B.
    Velickovic, A. Damjanovic
    Tomasevic, Z.
    Spasojevic, I. Bozovic
    Dzodic, R.
    Zdrale, Z.
    Juranic, Z.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S214 - S214
  • [37] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
    Bartsch, Rupert
    Rottenfusser, Andrea
    Wenzel, Catharina
    Dieckmann, Karin
    Pluschnig, Ursula
    Altorjai, Gabriela
    Rudas, Margaretha
    Mader, Robert M.
    Poetter, Richard
    Zielinski, Christoph C.
    Steger, Guenther G.
    JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) : 311 - 317
  • [38] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
    Rupert Bartsch
    Andrea Rottenfusser
    Catharina Wenzel
    Karin Dieckmann
    Ursula Pluschnig
    Gabriela Altorjai
    Margaretha Rudas
    Robert M. Mader
    Richard Poetter
    Christoph C. Zielinski
    Guenther G. Steger
    Journal of Neuro-Oncology, 2007, 85 : 311 - 317
  • [39] Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
    Peintinger, F.
    Buzdar, A. U.
    Kuerer, H. M.
    Mejia, J. A.
    Hatzis, C.
    Gonzalez-Angulo, A. M.
    Pusztai, L.
    Esteva, F. J.
    Dawood, S. S.
    Green, M. C.
    Hortobagyi, G. N.
    Symmans, W. F.
    ANNALS OF ONCOLOGY, 2008, 19 (12) : 2020 - 2025
  • [40] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients? Reply
    Yoshida, Atsushi
    Hayashi, Naoki
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 329 - 329
12345